Targeted gene mutation approaches to the study of anxiety-like behavior in mice

Neuroscience and Biobehavioral Reviews

Volumn 25, Issue 3, 2001, Pages 261-273

  Holmes, Andrew ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

5 HT receptors; Anxiety; Behavior; Corticotropin releasing hormone; GABAA receptor; Gene; Genetic background; Knockout; Mouse; Transgenic

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING); ANXIOLYTIC AGENT; BENZODIAZEPINE; CATECHOL METHYLTRANSFERASE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; SEDATIVE AGENT; UNCLASSIFIED DRUG;

AMNESIA; ANXIETY; ARTICLE; BEHAVIOR; BEHAVIOR DISORDER; DRUG EFFECT; GENE FUNCTION; GENE MUTATION; GENE TARGETING; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM;

EID: 0034985694     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(01)00012-4     Document Type: Review

References (152)

1. Behavior in mice with targeted disruption of single genes
2. The new mouse genetics: Altering the genome by gene targeting
3. Manipulating the genome by homologous recombination in embryonic stem cells
4. Unusual behavioral phenotypes of inbred mouse strains
5. Knockout mouse fault lines
6. Inducible gene expression in the nervous system of transgenic mice
7. Manipulation of transgenes by site-specific recombination: Use of Cre recombinase
8. Inducible gene targeting in mice
9. Genetic enhancement of learning and memory in mice
10. Control of memory formation through regulated expression of a CaMK11 transgene
11. Ethologically-based animal models of anxiety disorders
12. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research
13. Can social interaction be used to measure anxiety?
14. Exploratory behavior models of anxiety in mice
15. Emotional behavior in the rat. I. Defecation and urination as measures of individual differences in emotionality
16. Species-specific behavior and acquisition of avoidance behavior in rats
17. Thigmotaxis as a test for anxiolytic activity in rats
18. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses
19. Passive and active reactions to fear-eliciting stimuli
20. A simple genetic basis for a complex psychological trait in laboratory mice
21. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice
22. D3 dopamine receptor-deficient mouse: Evidence for reduced anxiety
23. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines
24. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines
25. Actions of sulpiride and tiapride in a simple model of anxiety in mice
26. Characterization of benzodiazepine-sensitive behaviors in the A/J and C57BL/6J inbred strains of mice
27. Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents
28. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety
29. The relation between fear induced by novel stimulation and exploratory behaviour
30. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour
31. Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
32. The use of a plus-maze to measure anxiety in the mouse
33. Trial 2 in the elevated plus-maze: A different form of fear?
34. Multiple-test study of anxiety-related behaviours in six inbred rat strains
35. Responses of Swiss-Webster mice to repeated plus-maze experience: Further evidence for a qualitative shift in emotional state?
36. Diazepam changes risk assessment in an anxiety/defense test battery
37. Anxiety enhancement in the murine elevated plus maze by immediate prior exposure to social stressors
38. Stretched attend posture, a non-social form of ambivalence, is sensitive to a conflict-reducing drug action
39. Antipredator defensive behaviors in a visible burrow system
40. The ambivalent behaviour 'stretched approach posture' in the rat as a paradigm to characterize anxiolytic drugs
41. Risk assessment behaviour: Evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test
42. Corticosterone response to the plus-maze: High correlation with risk assessment in rats and mice
43. Anxiety, motor activation, and maternal-infant interactions in 5HT1B knockout mice
44. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice
45. Behavioural and pharmacological characterisation of the elevated 'zero-maze' as an animal model of anxiety
46. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase
47. The free-exploratory paradigm: An effective method for measuring neophobic behaviour in mice and testing potential neophobia-reducing drugs
48. Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues
49. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development
50. Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli
51. The elevated plus-maze: Pharmacology, methodology and ethology
52. Effects of floor surface and environmental illumination on exploratory activity in the elevated plus-maze
53. The influence of open arm ledges and maze experience in the elevated plus-maze
54. Comparative analysis of anxiety-like behavior in partition and plus-maze tests after agonistic interactions in mice
55. Interindividual variability in Swiss male mice: Relationship between social factors, aggression, and anxiety
56. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA
57. Role of the dorsomedial hypothalamus in mediating the response to benzodiazepines on trial 2 in the elevated plus-maze test of anxiety
58. Influence of spatial and temporal manipulations on the anxiolytic efficacy of chlordiazepoxide in mice previously exposed to the elevated plus-maze
59. Genetics of mouse behavior: Interactions with laboratory environment
60. Behavioral phenotyping of transgenic and knockout mice: Experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests
61. Proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice
62. Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment
63. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism
64. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation
65. New animal models of anxiety
66. Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics
67. Fear-potentiated startle in two strains of inbred mice
68. Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in startle increases produced by conditioned versus unconditioned fear
69. Conditioned defensive burying: A new paradigm for the study of anxiolytic agents
70. Behavioral stress response of genetically selected aggressive and nonaggressive wild house mice in the shock-probe/defensive burying test
71. Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor
72. Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT(1A) receptor antagonists
73. Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: Effects of acute and chronic treatment with alprazolam
74. Differences in fear motivated behaviors among inbred mouse strains
75. Gene-targeting studies: New methods, old problems
76. Gene-targeting studies of mammalian behavior: Is it the mutation or the background genotype?
77. Mice, gene targeting and behaviour: More than just genetic background
78. Mutant mice and neuroscience: Recommendations concerning genetic background. Banbury Conference on genetic background in mice
79. Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains
80. Anxiolytic-like effects of yohimbine in the murine plus-maze: Strain independence and evidence against alpha 2-adrenoceptor mediation
81. Flumazenil induces benzodiazepine partial agonist-like effects in BALB/c but not C57BL/6 mice
82. Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice
83. Baseline exploratory activity predicts anxiolytic responsiveness to diazepam in five mouse strains
84. Link between emotional memory and anxiety states: A study by principal component analysis
85. Hypoexpression of benzodiazepine receptors in the amygdala of neophobic BALB/c mice compared to C57BL/6 mice
86. Assessing the effects of the 129/Sv genetic background on swimming navigation learning in transgenic mutants: A study using mice with a modified beta-amyloid precursor protein gene
87. Assessment of learning by the Morris water task and fear conditioning in inbred mouse strains and F1 hybrids: Implications of genetic background for single gene mutations and quantitative trait loci analyses
88. Inbred strain differences in prepulse inhibition of the mouse startle response
89. Assessment of locomotor activity, acoustic and tactile startle, and prepulse inhibition of startle in inbred mouse strains and F1 hybrids: Implications of genetic background for single gene and quantitative trait loci analyses
90. Heritability of nociception I: Responses of 11 inbred mouse strains on 12 measures of nociception
91. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations
92. Behavioural performance in three substrains of mouse strain 129
93. Pharmacologic and behavioral responses of inbred C57BL/6J and strain 129/SvJ mouse lines
94. Behavior and mutagenesis screens: The importance of baseline analysis of inbred strains
95. Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene
96. Striking changes in anxiety in Huntington's disease transgenic mice
97. Trends in recommendations for the pharmacotherapy of anxiety disorders by an international expert panel, 1992-1997
98. The GABA-benzodiazepine interaction fifteen years later
99. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes
100. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: Classification on the basis of subunit structure and receptor function
101. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes
102. Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout mice
103. Normal electrophysiological and behavioral responses to ethanol in mice lacking the long splice variant of the gamma2 subunit of the gamma-aminobutyrate type A receptor
104. Benzodiazepine-insensitive mice generated by targeted disruption of the gamma 2 subunit gene of gamma-aminobutyric acid type A receptors
105. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder
106. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: Preliminary results from a quantitative PET study
107. Cleft palate in mice with a targeted mutation in the gamma-aminobutyric acid-producing enzyme glutamic acid decarboxylase 67
108. Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase
109. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase
110. Update on the diagnosis and treatment of social anxiety disorder
111. Selective enhancement of emotional, but not motor, learning in monoamine oxidase A-deficient mice
112. Increased stress response and beta-phenylethylamine in MAOB-deficient mice
113. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior
114. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics
115. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors
116. Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice
117. OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1 neurons
118. Iversen SD5-HT and anxiety
119. Current treatments of the anxiety disorders in adults
120. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders
121. Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission
122. Perturbed dentate gyrus function in serotonin 5-HT2C receptor mutant mice
123. A paradoxical locomotor response in serotonin 5-HT(2C) receptor mutant mice
124. Serotonin receptor 1A knockout: An animal model of anxiety-related disorder
125. Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors
126. Increased anxiety of mice lacking the serotonin1A receptor
127. Genetic inactivation of the Serotonin(1A) receptor in mice results in downregulation of major GABA(A) receptor alpha subunits, reduction of GABA(A) receptor binding, and benzodiazepine-resistant anxiety
128. 5-HT1B receptor knock out-behavioral consequences
129. 5-HT1B receptor knock-out mice exhibit increased exploratory activity and enhanced spatial memory performance in the Morris water maze
130. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety
131. Corticotropin releasing factor produces behavioural activation in rats
132. Activating and 'anxiogenic' effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone
133. Overproduction of corticotropin-releasing factor in transgenic mice: A genetic model of anxiogenic behavior
134. Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated
135. Behavioral responses to stress are intact in CRF-deficient mice
136. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH
137. Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats
138. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1
139. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor
140. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: Comparison with CRF1 receptor mRNA expression
141. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior
142. Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain
143. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress
144. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2
145. Diagnosis and classification of psychopathology: Challenges to the current system and future directions
146. Comparison of different behavioral test situations used in psychopharmacology for measurement of anxiety
147. Animal models of different anxiety states
148. Animal models of 'anxiety': Where next?